drugset
drugset / Trial / NCT04531150

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

NCT04531150 ↗

Phase 1 Completed 40 enrolled Inversago Pharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Single center, randomized, double-blinded, placebo-controlled, single ascending-dose study for the evaluation of the safety, tolerability, and PK following single oral doses of INV-101.

Timeline

Start
2020-09-08
Primary completion
2021-01-16
Completion
2021-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject INV-101 Unknown 20 mg Oral
Subject INV-101 Unknown 80 mg Oral
Subject INV-101 Unknown 160 mg Oral
Subject INV-101 Unknown 320 mg Oral
Subject INV-101 Unknown 500 mg Oral

Indications

No indication recorded.